Minocycline for the treatment of amyotrophic lateral sclerosis: Neuroprotector or neurotoxin? Reflections on another failure of translational medicine;Minociclina para el tratamiento de la esclerosis lateral amiotrófica: ¿Neuroprotectora o neurotóxica? Reflexiones sobre otro fracaso de la medicina traslacional

Neurologia

Volumn 23, Issue 8, 2008, Pages 484-493

  Gámez, Josep ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Amyotrophic lateral sclerosis; Clinical trial; Lou Gehrig's disease; Minocycline; Motor neuron disease; Neuroprotection; Neurotoxicity; Translational medicine

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ARIMOCLOMOL; BCL2 RELATED PROTEIN A1; BETA INTERFERON; BIOLOGICAL MARKER; CALCIUM ANTAGONIST; CEFTRIAXONE; CLOZAPINE; CREATINE; DIMETHADIONE; GABAPENTIN; HEAT SHOCK PROTEIN 70; IMMUNOMODULATING AGENT; LAMOTRIGINE; MEMANTINE; MINOCYCLINE; NEUROTOXIN; NEUROTROPHIC FACTOR; NEUROTROPHIN RECEPTOR P75; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PENICILLAMINE; PLACEBO; PROTEIN P35; PROTEIN P53; RILUZOLE; TALAMPANEL; TAMOXIFEN; TOPIRAMATE; UNINDEXED DRUG;

ALLERGIC ENCEPHALOMYELITIS; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL MODEL; APOPTOSIS; AUTOPHAGY; DISEASE COURSE; DISEASE EXACERBATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ENCEPHALITIS; GASTROINTESTINAL SYMPTOM; GINSENG; HUMAN; HUNTINGTON CHOREA; HYPOXIA; IMPAIRED GLUCOSE TOLERANCE; MAXIMUM PERMISSIBLE DOSE; MULTIPLE SCLEROSIS; NERVE FIBER TRANSPORT; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN AGGREGATION; RETROVIRUS INFECTION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; TRANSGENIC MOUSE; UREA BLOOD LEVEL;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC; MINOCYCLINE; NEUROPROTECTIVE AGENTS; NEUROTOXINS; TREATMENT OUTCOME;

EID: 55849140172     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: None     Document Type: Review

References (170)

1. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al.; Western ALS Study Group. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomized trial. Lancet Neurol 2007;6:1045-53.
2. Benatar M. Lost in translation: treatment trials in the SOD 1 mouse and in human ALS. Neurobiol Dis 2007;26:1-13.
3. Saivin S, Hovin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 1988;15:355-66.
4. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 1998;95:15769-74.
5. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minoeycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 1999;96:13496-500.
6. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in neurology. Lancet Neurol 2004;3:744-51.
7. Festoff BW, Ameenuddin S, Arnold PM, Wong A, Santacruz KS, Citron BA. Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury. J Neurochem 2006;97:1314-26.
8. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417:74-8.
9. Kriz J, Nguyen M, Julien J. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002;10:268-78.
10. Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 2002;13:1067-70.
11. Tikka TM, Vartianen NE, Goldsteins G, Oja SO, Andersen PM, Marklund SL, et al. Minocycline prevents neurotoxicity induced by cerebrospinal fluid patients with motor neurone disease. Brain 2002;722-31.
12. Shaw PJ. Toxicity of CSF in motor neurone disease: a potential route to neuroprotection. Brain 2002;25:693-4.
13. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000;6:797-801.
14. Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E, et al. Minocycline inhibits caspase-independent and dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci USA 2003;100:10483-7.
15. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW. Targeting leukocyte MMP and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002;125:1297-308.
16. Popovic N, Schubart A, Goetz BD, Zhang SC, Linington C, Duncan ID. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 2002;51:215-23.
17. Nessler S, Dodel R, Bittner A, Reuss S, Du Y, Hemmer B, et al. Effect of minocycline in experimental autoimmune encephalomyelitis. Ann Neurol 2002;52:689-90.
18. Wells J, Hurlbert J, Fehlings M, Yong VW. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury. Brain 2003;126:1628-37.
19. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 2001;98:14669-74.
20. Hunter CL, Bachman D, Granholm AC. Minocycline prevents cholinergic loss in a mouse model of Down's syndrome. Ann Neurol 2004;56:675-88.
21. Huntington Study Group. Minocycline safety and tolerability in Huntington disease. Neurology 2004;63:547-9.
22. Zink MC, Uhrlaub J, DeWitt J, Voelker T, Bullock B, Mankowski J, et al. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 2005;293:2003-11.
23. Zhang W, Narayanan M, Friedlander RM. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol 2003;53:267-70.
24. Kriz J, Gowing G, Julien JP. Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Ann Neurol 2003;53:429-36.
25. Milane A, Fernández C, Vautier S, Bensimon G, Meininger V, Farinotti R. Minocycline and riluzole brain disposition: interactions with p-glycoprotein at the blood-brain barrier. J Neurochem 2007;103:164-73.
26. Seabrook TJ, Jiang L, Maier M, Lemere CA. Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia 2006;53:776-82.
27. Couzin J. ALS trial raises questions about promising drug. Science 2007;318:1227.
28. Gordon PH, Moore DH, Gelinas DF, Qualls C, Meister ME, Werner J, et al. Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology 2004;62:1845-7.
29. Pontieri FE, Ricci A, Pellicano C, Benincase D, Buttarelli FR. Minocycline in amyotrophic lateral sclerosis: a pilot study. Neurol Sci 2005;26:285-7.
30. Giuliani F, Fu SA, Metz LM, Yong VW. Effective combination of minocycline and interferon-beta in a model of multiple sclerosis. J Neuroimmunol 2005;165:83-91.
31. Bandini F. Minocycline in neurological diseases. Lancet Neurol 2005,4:138-9.
32. Tabrizi SJ, Blamire AM, Manners DN, Rajagopalan B, Styles P, Schapira AH, et al. High-dose creatine therapy for Huntington's disease: a two-year clinical and MRS study. Neurology 2005;64:1655-6.
33. Reynolds N. Revisiting safety of minocycline neuroprotection in Huntington's disease. Mov Disord 2007;22:292.
34. Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, Rapoport A, et al. Minocylcine treatment in acute stroke. An open-label, evaluator-blinder study. Neurology 2007;69:1404-10.
35. Diguet E, Fernagut PO, Wei X, Du Y, Rouland R, Gross C, et al. Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur J Neurosci 2004;19:3266-76.
36. Tsuji M, Wilson MA, Lange MS, Johnston MV. Minocycline worsens hypoxic-ischemic brain injury in a neonatal mouse model. Exp Neurol 2004;189:58-65.
37. Yang L, Sugama S, Chirichigno JW, Gregorio J, Lorenzl S, Shin DH, et al. Minocycline enhances MPTP toxicity to dopaminergic neurons. J Neurosci Res 2003;74:278-85.
38. Swash M, Schwartz MS. What do we really know about amyotrophic lateral sclerosis? J Neurol Sci 1992;113:4-16.
39. Eisen A. Amyotrophic lateral sclerosis is a multifactorial disease. Muscle Nerve 1995;18:741-5.
40. Tandan R, Bromberg MB, Forshew D, Fries TJ, Badger GJ, Carpenter J, et al. A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data. Neurology 1996;47:1220-6.
41. Andersen JK. Oxidative stress in neurodegeneration: cause or consequence? Nat Med 2004;10(Suppl.):S18-25.
42. Bogdanov M, Brown RH, Matson W, Smart R, Hayden D, O'Donnell H, et al. Increased oxidative damage to DNA in ALS patients. Free Radic Biol Med 2000;29:652-8.
43. Bossy-Wetzel E, Schwarzenbacher R, Lipton SA. Molecular pathways to neurodegeneration. Nat Med 2004;10(Suppl.):S2-9.
44. Bruijn LI, Cleveland DW. Mechanisms of selective motor neuron death in ALS: insights from transgenic mouse models of motor neuron disease. Neuropathol Appl Neurobiol 1996;22:373-87.
45. Bruijn LI, Miller TM, Cleveland DW. Unravelling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 2004;27:723-49.
46. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001;2:806-18.
47. Demestre M, Parkin-Smith G, Petzold A, Pullen AH. The pro and the active form of matrix metalloproteinase-9 is increased in serum of patients with amyotrophic lateral sclerosis. J Neuroimmunol 2005;159:146-54.
48. Deng HX, Hentati A, Tainer JA, Iqbal Z, Cayabyab A, Hung WY, et al. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. Science 1993;261:1047-51.
49. Di Giorgio FP, Carrasco MA, Siao MC, Maniatis T, Eggan K. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosc 2007;10:608-14.
50. Gámez J, Corbera-Bellalta M, Nogales G, Raguer N, Garcia-Arumí E, Badía-Canto M, et al. Mutational analysis of the Cu/Zn Superoxide dismutase gene in a Catalan ALS population: Should all sporadic ALS cases also be screened for SOD1? J Neurol Sci 2006;247:21-8.
51. Gámez J, Barceló MJ, Muñoz X, Carmona F, Cuscó I, Baiget M, et al. Survival and respiratory decline are not related to homozygous SMN2 deletions in ALS patients. Neurology 2002;59:1456-60.
52. Gámez J. Apoptosis y ELA. En: Mora Pardiñas JS, editor. Esclerosis lateral amiotrófica. Una enfermedad tratable. Barcelona: Prous Science, 1999; p. 265-74.
53. Li M, Ona VO, Guégan C, Chen M, Jackson-Lewis V, Andrews LJ, et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 2000;288:335-9.
54. Li L, Zhang X, Le W. Altered macroautophagy in the spinal cord of SOD1 mutant mice. Autophagy 2008;4:290-3.
55. Liu R, Narla RK, Kurinov I, Li B, Uckun FM. Increased hydroxyl radical production and apoptosis in PC12 neuron cells expressing the gain-of-function mutant G93A SOD1 gene. Radiat Res 1999;151:133-41.
56. Matyja E, Taraszewska A, Naganska E, Rafalowska J, Gebarowska J. Astroglial alterations in amyotrophic lateral sclerosis (ALS) model of slow glutamate excitotoxicity in vitro. Folia Neuropathol 2005;43:7-13.
57. Nguyen MD, Boudreau M, Kriz J, Couillard-Després S, Kaplan DR, Julien JP. Cell cycle regulators in the neuronal death pathway of amyotrophic lateral sclerosis caused by mutant superoxide dismutase 1. J Neurosci 2003;23:2131-40.
58. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001;28:131-8.
59. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62.
60. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001;344:1688-700.
61. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008;319:1668-72.
62. Andersen PM, Borasio GD, Dengler R, Hardiman O, Kollewe K, Leigh PN, et al.; EALSC Working Group. Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence-based review with good practice points. EALSC Working Group. Amyotroph Lateral Scler 2007;8:195-213.
63. Beck M, Karch C, Wiese S, Sendtne M. Motor neuron cell death and neurotrophic factors: basic models for development of new therapeutic strategies in ALS. Amyotrophic Lateral Scler Other Motor Neuron Disord 2001;2(Suppl. 1):55-68.
64. Bradley WG, Hedlund W, Cooper C, Desousa GJ, Gabbai A, Mora JS, et al. A double-blind controlled trial of bovine brain gangliosides in amyotrophic lateral sclerosis. Neurology 1984;34:1079-082.
65. Brooke MH, Florence JM, Heller SL, Kaiser KK, Phillips D, Gruber A, et al. Controlled trial of thyrotropin releasing hormone in amyolrophic lateral sclerosis. Neurology 1986;36:146-51.
66. Brooks BJ. Clinical evaluation of ALS drugs. Neurology 1997; 48(Suppl. 4):S23-7.
67. Chiò A, Cucatto A, Terreni A, Schiffer D. Reduced glutathione in amyotrophic lateral sclerosis: an open, cross-over, randomized trial. Ital J Neurol Sci 1998;19:363-6.
68. Desnuelle C, Dib M, Garrel C, Favier A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2001;2:9-18.
69. Drachmen DB, Chaudhry V, Cornblath D, Kuncl RW, Pestronk A, Clawson L, et al. Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann Neurol 1994;35:142-50.
70. Drachman DB, Chaudhry V, Cornblath D, Kuncl RW, Pestronk A, Clawson L, et al. Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann Neurol 1994;35:142-50.
71. Eisen A, Stewart H, Schulzer M, Cameron D. Anti-glutamate therapy in amyotrophic lateral sclerosis: a trial using lamotrigine. Can J Neurol Sci 1993;20:297-301.
72. Gourie-Devi M, Nalini A, Subbakrishna DK. Temporary amelioration of symptoms with intravenous cyclophosphamide in amyotrophic lateral sclerosis. J Neurol Sci 1997;150:167-72.
73. Graf M, Ecker D, Horowski R, Kramer B, Riederer P, Gerlach M, et al.; German vitamin E/ALS Study Group. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm 2005;112:649-60.
74. Harrington H, Hallett M, Tyler HR. Ganglioside therapy for amyotrophic lateral sclerosis: a double-blind controlled trial. Neurology 1984;34:1083-5.
75. Kennel P, Revah F, Bohme GA, Bejuit R, Gallix P, Stutzmann JM, et al. Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuronopathy (pmn). J Neurol Sci 2000;180:55-61.
76. Bensimon G, Lacomblez L, Meininger V, and The ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-91.
77. Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, et al. Neuroprotective effects of creatine in a transgenic animal model of ALS. Nat Med 1999;5:347-50.
78. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V, for the Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425-31.
79. Lai EC, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 1997;49:1621-30.
80. MacGowan DJ, Scelsa SN, Imperato TE, Liu KN, Baron P, Polsky B. A controlled study of reverse transcriptase in serum and CSF of HIV-negative patients with ALS. Neurology 2007;68:1944-6.
81. McCormick AL, Brown Jr. RH, Cudkowicz ME, Al-Chalabi A, Garson JA. Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate. Neurology 2008;70:278-83.
82. Ryu H, Smith K, Camelo SI, Carreras I, Lee J, Iglesias AH, et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 2005;93:1087-98.
83. Traynor BJ, Bruijn L, Conwit R, Beal F, O'Neill G, Fagan SC, et al. Neuroprotective agents for clinical trials in ALS. A systematic assessment. Neurology 2006;67:20-7.
84. Ralph GS, Radcliffe PA, Day DM, Carthy JM, Leroux MA, Lee DC, et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 2005;11:429-33.
85. Xia X, Zhou H, Huang Y, Xu Z. Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo. Neurobiol Dis 2006;23:578-86.
86. Dengler R, von Neuhoff N, Bufler J, Krampfl K, Peschel T, Grosskreutz J. Amyotrophic lateral sclerosis: new developments in diagnostic markers. Neurodegener Dis 2005;2:177-84.
87. Dupuis L, Muller A, Meininger V, Loeffler JP. Mécanismes moléculaires de la sclérose latérale amyotrophique: apports récents de l'analyse de modèles animaux. Rev Neurol (Paris) 2004;160:35-43.
88. Houi K, Kobayashi T, Kato S, Mochio S, Inoue K. Increased plasma TGF-1 in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2002;106:299-301.
89. Ilzecka J. Prostaglandin E2 is increased in amyotrophic lateral sclerosis patients. Acta Neurol Scand 2003;108:125-9.
90. Ilzecka J. Cerebrospinal fluid Flt3 ligand level in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2006;114:205-9.
91. Ilzecka J. Decreased cerebrospinal fluid cytochrome c levels in patients with amyotrophic lateral sclerosis. Scand J Clin Lab Invest 2007;67:264-9.
92. Ilzecka J. Decreased serum endoglin level in patients with amyotrophic lateral sclerosis: a preliminary report. Scand J Clin Lab Invest 2008;68:1-5.
93. Ilzecka J. Decreased serum-soluble TRAIL levels in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2008; 117:343-6.
94. Nagata T, Nagano I, Shiote M, Narai H, Murakami T, Hayashi T, et al. Elevation of MCP-1 and MCP-1/VEGF ratio in cerebrospinal fluid of amyotrophic lateral sclerosis patients. Neurol Res 2007;29:772-6.
95. Pasinetti GM, Ungar LH, Lange DJ, Yemul S, Deng H, Yuan X, et al. Identification of potential CSF biomarkers in ALS. Neurology 2006;66:1218-22.
96. Pradat PF, Bruneteau G, González de Aguilar JL, Dupuis L, Jokic N, Salachas F, et al. Muscle Nogo-a expression is a prognostic marker in lower motor neuron syndromes. Ann Neurol 2007;62:15-20.
97. Ranganathan S, Jordan K, Sathanoori R, Henry S, Wood P, Urbinelli L, et al. Identification of ALS specific biomarkers by protein profiling of cerebral spinal fluid. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4(Suppl. 1):12.
98. Sekizawa T, Openshaw H, Ohbo K, Sugamura K, Itoyama Y, Niland JC. Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J Neurol Sci 1998;154:194-9.
99. Simpson EP, Henry YK, Henkel JS, Smith RG, Appel SH. Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden. Neurology 2004;62:1758-65.
100. Tsuboi Y, Yamada T. Increased concentration of C4d complement protein in CSF in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1994;57:859-61.
101. Zetterberg H1 Jacobsson J, Rosengren L, Blennow K, Andersen PM. Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur J Neurol 2007;14:1329-33.
102. Zoccolella S, Simone IL, Lamberti P, Samarelli V, Tortelli R, Serlenga L, et al. Elevated plasma homocysteine levels in patients with amyotrophic lateral sclerosis. Neurology 2008;70:222-5.
103. Alexander GM, Erwin KL, Byers N, Deitch JS, Augelli BJ, Blankenhorn EP, et al. Effect of transgene copy number on survival in the G93A SOD1 transgenic mouse model of ALS. Brain Res Mol Brain Res 2004;130:7-15.
104. Cork LC, Kitt CA, Struble RG, Griffin JW, Price DL. Animal models of degenerative neurological disease. Prog Clin Biol Res 1987;229:241-69.
105. Nagai M, Aoki M, Miyoshi I, Kato M, Pasinelli P, Kasai N, et al. Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis associated mutations develop motor neuron disease. J Neurosci 2001;23:9246-54.
106. Rockenstein E, Crews L, Masliah E. Transgenic animal models of neurodegenerative diseases and their application to treatment development. Adv Drug Deliv Rev 2007;59:1093-102.
107. Doble A, Kennel P. Animal models of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:301-12.
108. Ghadge GD, Wang L, Sharma K, Monti AL, Bindokas V, Stevens FJ, et al. Truncated wild-type SOD1 and FALS-linked mutant SOD1 cause neural cell death in the chick embryo spinal cord. Neurobiol Dis 2006;21:194-205.
109. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, et al. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science 1994;264:1772-5.
110. Haenggeli C, Kato AC. Differential vulnerability of cranial motor neurons in mouse models with motor neuron degeneration. Neurosci Lett 2002;335:39-43.
111. Lange DJ, Murphy PL, Diamond B, Appel V, Lai EC, Younger DS, et al. Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch Neurol 1998;55:93-6.
112. Avossa D, Grandolfo M, Mazzarol F, Zatta M, Ballerini L. Early signs of motor neuron vulnerability in a disease model system: characterization of transverse slice cultures of spinal cord isolated from embryonic ALS mice. Neuroscience 2006;138:1179-94.
113. ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rhCNTF) in amyotrophic lateral sclerosis. Neurology 1996;46:1244-9.
114. Beghi E, Chio A, Inghilleri M, Mazzini L, Micheli A, Mora G, et al. A randomized controlled trial of recombinant Interferon beta-1a in ALS. Neurology 2000;54:469-74.
115. Borasio GD, Robberecht W, Leigh PN, Emile J, Guiloff RJ, Jerusalem F, et al; European ALS/IGF-I Study Group. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. Neurology 1998;51:583-6.
116. Brooks B, Sanjak M, Roelke KA, Parnell JP, Peper SM, Houdek AM, et al. Tamoxifen[tri-phenylethylene protein kinase inhibitor] phase Ii dose-escalation clinical trial in ALS: Study design and safety results in first 50 patients. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4(Suppl. 1):30.
117. Cudkowicz M, Shefner J, Schoenfeld D, Brown RJ, Johnson H, Qureshi M, et al.; Northeast ALS Consortium. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurol 2003;61:456-64.
118. Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 2006;60:22-31.
119. Ferrante KL, Shefner J, Zhang H, Betensky R, O'Brien M, Yu H, et al. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology 2005;65:1834-6.
120. Gredal O, Werdelin L, Bak S, Christensen PB, Boysen G, Kristensen MO, et al. A clinical trial of dextromethorphan in amyotrophic lateral sclerosis. Acta Neurol Scand 1997;96:8-13.
121. Groeneveld GJ, Veldink JH, van der Tweel I, Kalmijn S, Beijer C, de Visser M, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003;53:437-45.
122. Levy G, Kaufmann P, Buchsbaum R, Montes J, Barsdorf A, Arbing R, et al. A two-stage design for a phase 11 clinical trial of coenzyme Q10 in ALS. Neurology 2006;66:660-3.
123. Louwerse ES, Weverling GJ, Bossuyt PM, Meyjes FE, de Jong JM. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol 1995;52: 559-64.
124. Meininger V, Asselain B, Guillet P, Leigh PN, Ludolph A, Lacomblez L, et al.; Pentoxifylline European Group. Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial. Neurology 2006;66:88-92.
125. Meininger V, Bensimon G, Bradley WR, Brooks B, Douillet P, Eisen AA, et al. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:107-17.
126. Miller R, Moore DH, Young L, Armon C, Barohn RJ, Bromberg MB, et al.; WALS Study Group. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 1996;47:1383-8.
127. Miller RG, Moore DH, Gelinas DF, Dronsky B, Mendoza M, Barohn R, et al.; Western ALS Study Group. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001;56:843-8.
128. Miller RG, Petajan JH, Bryan WW, Armon C, Barohn RJ, Goodpasture JC, et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. Ann Neurol 1996;39:256-60.
129. Miller RG, Shepherd R, Dao H, Khramstov A, Mendoza M, Graves J, et al. Controlled trial of nimodipine in amyotrophic lateral sclerosis. Neuromuscul Disord 1996;6:101-4.
130. Miller RG, Smith SA, Murphy JR, Brinkmann JR, Graves J, Mendoza M, et al. A clinical trial of verapamil in amyotrophic lateral sclerosis. Muscle Nerve 1996;19:511-5.
131. Munsat TL, Taft J, Jackson IM, Andres PL, Hollander D, Skerry L, et al. Intrathecal thyrotropin-releasing hormone does not alter the progressive course of ALS: experience with an intrathecal drug delivery system. Neurology 1992;42:1049-53.
132. Ryberg H, Askmark H, Persson LI. A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters. Acta Neurol Scand 2003; 108:1-8.
133. Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, et al.; NEALS Consortium. A clinical trial of creatine in amyotrophic lateral sclerosis. Neurology 2004;63:1656-61.
134. Tandan R, Bromberg MB, Forshew D, Fries TJ, Badger GJ, Carpenter J, et al. A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. clinical, functional, and maximum isometric torque data. Neurology 1996;47:1220-6.
135. The BDNF Study Group. A controlled trial of recombinant methionyl human BDNF in ALS. Neurology 1999;52:1427-33.
136. The Italian ALS Study Group. Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure? Neurology 1993;43:2466-70.
137. Scott S, Kranz JE, Cole J, Lincecum JM, Thompson K, Kelly N, et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler 2008;9:4-15.
138. De Carvalho M, Costa J, Swash M. Clinical trials in ALS; a review of the role of clinical and neurophysiological measurements. Amyotroph Lateral Scler Other Motor Neuron Disord 2005;6:202-12.
139. Ludolph AC, Sperfeld AD. Preclinical trials-an update on translational research in ALS. Neurodegener Dis 2005;2:215-9.
140. nd ENMC international workshop. Amyotroph Lateral Scler 2007;8:217-23.
141. Meininger V. Clinical Trials in ALS: what did we learn from recent trials in Humans? Neurodegener Dis 2005;2:208-14.
142. Palesch YY, Tilley BC. An efficient multi-stage, single-arm phase II futility design for ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5(Suppl. 1):55-6.
143. Schoenfeld D, Cudkowicz M. Design of phase II ALS clinical trials. Amyotroph Lateral Scler 2007;8(Suppl. 1):60-1.
144. Swash M. Learning from failed trials in ALS. Lancet Neurol 2007;6.1034-5.
145. Swartz A, Shefner J, Yu H, Thornell B, Sherman A, Cudkowicz M. Design and implementation of a multi-phase, adaptive-design clinical trial for subjects with ALS. Amyotrophic Lateral Sclerosis 2007;8(Suppl. 1):142-3.
146. Miller RG, Moore DH, Gordon P, Florence JM, Verheijde JL, Spitalny GM, et al.; ALS/minocycline Study Group. Is the ALSFRS-R rate of decline linear over time? Amyotroph Lateral Scler 2007; 8(Suppl. 1):140.
147. Grasso D, Simpson E, Tellier J, Barber J, Shefner J, Cudkowicz M; NEALS Consortium. Assessment of the clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler 2007;8(Suppl. 1):140-1.
148. Moore DH, Gordon PH, Spitalny GM, Doorish C, Santos T, Miller RG. What endpoint is appropriate for ALS clinical trials? Amyotroph Lateral Scler 2007;8(Suppl. 1):140-1.
149. Ansevin CF. Treatment of ALS with pleconaril. Neurology 2001;56:691-2.
150. Cheung YK, Gordon PH, Levin B. Selecting promising ALS therapies in clinical trials. Neurology 2006;67:1748-51.
151. th International Symposium on ALS/MND. Yokohama, Japan. 30 Nov-2 Dec 2006. Clinical Work in Progress and Care Practice and Scientific Work in Progress. Abstract CW187, 10.
152. Fornai F, Longone P, Cafaro P, Kastsiuchenka O, Ferrucci M, Manca ML, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2008;105:2052-7.
153. Fornai F, Longone P, Ferrucci M, Lenzi P, Isidoro C, Ruggieri S, et al. Autophagy and amyotrophic lateral sclerosis: the multiple roles of lithium. Autophagy 2008;4:527-30.
154. Verschueren A, Lacomblez L, Abitbol J-L, Cuvier V, Jouve E, Blin O, et al. TRO19622 is well tolerated and target plasma concentrations are obtained at doses 250/500 mg once a day in a one month ALS phase 1b, add-on to riluzole, clinical study. Amyotroph Lateral Scler 2007;8(Suppl. 1):59-60.
155. Lomen-Hoerth C, Squire L, Scott S, McCarthy J, Olney R. Double-blind, placebo controlled safety study of ritonavir and hydroxyurea in patients with ALS. Amyotroph Lateral Scler 2007;8(Suppl. 1):60.
156. Chio A, Mora G, Caponnetto C, Siciliano G, Sabatelli M, La Bella V, et al. A multicentre trial on G-CSF in Amyotrophic Lateral Sclerosis. Amyotroph Lateral Scler 2007;8(Suppl. 1):143-4.
157. Drory V, Artmonov I, Nefussy B. Evaluation of treatment with Rasagiline in patients with Amyotrophic Lateral Sclerosis. Amyotroph Lateral Scler 2007;8(Suppl. 1):143-4.
158. Piepers S, de Jong S, Veldink J, Groeneveld GJ, Sodaar P, Jansen M, et al. A randomized, placebo-controlled, sequential trial of valproic acid in ALS. Amyotroph Lateral Scler 2007;8 (Suppl. 1):145-6.
159. Scimè R, Leone G, Petrini M, Melazzini, Gualandi F, Omedè P, Tarella C. A multicentre trial on G-CSF in Arnyotrophic Lateral Sclerosis. Amyotroph Lateral Scler 2007;8(Suppl. 1):143-4.
160. Nakagawa N, Ohkubo H, Yoshino H. The long-term effect of edaravone in ALS patients. Amyotroph Lateral Scler 2007;8 (Suppl. 1):146.
161. Dibernardo A, Cudkowicz M, Shefner J, Groeneveld G, van den Berg L, Zhang H, et al. Combined analysis of creatine monohydrate trials in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2007;8(Suppl. 1):147-148.
162. Bedlack R, Hawes J, Pastula D, Heydt D, Burke P. A pilot trial of levetiracetam for cramps, spasticity and neuroprotection in patients with motor neuron diseases. Amyotroph Lateral Scler 2007;8(Suppl. 1):148.
163. Lange D, Seidel G, Benjamin D, Scott S, Vieira F. Pyrimethamine as a therapy for SOD1 associated FALS: early findings. Amyotroph Lateral Scler 2007;8(Suppl. 1):148-9.
164. Gargiulo Monachelli GM, Rodriguez GE, González Deniselle MC, de Nicola AF, Sica REP. Progesterone as a new treatment option for amyotrophic lateral sclerosis patients: open trial and survival analysis. Neurology 2008;70(Suppl. 1):A193.
165. Brooks BR, Bradley WG, Arnold R, Pope LE, Berg JE, Olney RK, et al.; Study Group AVP-9233. Dextromethorphan-quinidine (DMQ) treatment of pseudobulbar affect (PBA) in Amyotrophic Lateral Sclerosis (ALS). Amyotroph Lateral Scler 2006;7(Suppl. 1): 110.
166. Abitbol JL, Cuvier V, Bordet T, Drouot C, Berna P, Pruss R. Safety and pharmacokinetics of repeated doses of TRO19622, a drug candidate for the treatment of amyotrophic lateral sclerosis and spinal muscular atrophy. Amyotroph Lateral Scler 2006;7(Suppl. 1):112-3.
167. Cudkowicz M, Shefner J, Simpson E, Grasso D, Sherman A, Yu H, et al. A multicentre, dose ranging safety and pharmacokinetics study of arimoclomol in ALS. Amyotroph Lateral Scler 2006; 7(Suppl. 1):113.
168. Kaufmann P, Thompson JL, Levy G, Barsdorf AI, Buchsbaum R, Montes J, et al.; QALS Study Group. Is a phase III trial of coenzyme Q10 (CoQ10) for ALS justified? Results of the phase II randomized controlled trial of CoQ10 for ALS. Neurology 2008;70(Suppl. 1)A238.
169. Chiò A, Mora G, Caponnetto C, Siciliano G, Sabatelli M, La Bella V, et al. A phase I-II multicenter study on G-CSF in amyotrophic lateral sclerosis (STEMALS). Neurology 2008;70(Suppl. 1): A192.
170. Leigh PN, Meininger V, Bensimon G, Cudkowicz M, Robberecht W. Minocycline for patients with ALS. Lancet Neurol 2008;7:119-20.